Edwards Lifesciences (NYSE:EW) Releases Quarterly Earnings Results, Beats Expectations By $0.04 EPS

Edwards Lifesciences (NYSE:EW) issued its quarterly earnings data on Thursday. The medical research company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.74 by $0.04, FiscalAI reports. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The firm had revenue of $1.74 billion during the quarter, compared to the consensus estimate of $1.70 billion. Edwards Lifesciences updated its Q3 2026 guidance to 0.710-0.770 EPS and its FY 2026 guidance to 2.950-3.050 EPS.

Edwards Lifesciences Stock Performance

NYSE EW traded down $0.74 during trading hours on Thursday, reaching $83.63. 6,798,286 shares of the company were exchanged, compared to its average volume of 4,888,525. Edwards Lifesciences has a 1 year low of $72.30 and a 1 year high of $96.29. The business’s 50 day simple moving average is $87.65 and its 200-day simple moving average is $83.90. The company has a quick ratio of 3.63, a current ratio of 4.42 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $48.15 billion, a P/E ratio of 44.48, a P/E/G ratio of 2.12 and a beta of 0.86.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the company. BTIG Research upped their price target on Edwards Lifesciences from $100.00 to $110.00 and gave the stock a “buy” rating in a report on Tuesday, June 30th. Weiss Ratings restated a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Friday, July 17th. Canaccord Genuity Group set a $85.00 price objective on shares of Edwards Lifesciences and gave the stock a “hold” rating in a report on Friday, April 24th. Citigroup increased their target price on shares of Edwards Lifesciences from $101.00 to $110.00 and gave the company a “buy” rating in a report on Wednesday, July 8th. Finally, Evercore reissued an “outperform” rating and set a $100.00 price target on shares of Edwards Lifesciences in a research report on Monday, July 6th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and seven have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $98.95.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 1,019 shares of the stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $83.01, for a total transaction of $84,587.19. Following the completion of the transaction, the vice president directly owned 33,934 shares of the company’s stock, valued at $2,816,861.34. This represents a 2.92% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of the firm’s stock in a transaction that occurred on Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the sale, the vice president owned 98,611 shares of the company’s stock, valued at approximately $8,521,962.62. The trade was a 19.01% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 45,577 shares of company stock worth $3,855,527 over the last three months. 0.31% of the stock is currently owned by insiders.

Institutional Trading of Edwards Lifesciences

Several hedge funds have recently made changes to their positions in the company. Brighton Jones LLC bought a new stake in Edwards Lifesciences in the 4th quarter valued at about $266,000. NewEdge Advisors LLC increased its stake in shares of Edwards Lifesciences by 8.1% in the second quarter. NewEdge Advisors LLC now owns 35,637 shares of the medical research company’s stock worth $2,787,000 after purchasing an additional 2,665 shares in the last quarter. Sei Investments Co. increased its stake in shares of Edwards Lifesciences by 16.7% in the second quarter. Sei Investments Co. now owns 412,808 shares of the medical research company’s stock worth $32,285,000 after purchasing an additional 58,988 shares in the last quarter. Squarepoint Ops LLC raised its position in shares of Edwards Lifesciences by 277.7% in the second quarter. Squarepoint Ops LLC now owns 69,263 shares of the medical research company’s stock valued at $5,417,000 after purchasing an additional 50,924 shares during the period. Finally, Treasurer of the State of North Carolina raised its position in shares of Edwards Lifesciences by 0.4% in the second quarter. Treasurer of the State of North Carolina now owns 268,860 shares of the medical research company’s stock valued at $21,028,000 after purchasing an additional 1,065 shares during the period. 79.46% of the stock is currently owned by institutional investors.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.